Takeda Pharmaceutical Company Limited

Vividion Therapeutics, Inc.

Shota Kikuchi

Holger Monenschein

Holly Reichard

Huikai Sun

Maria Hopkins

Stephen A Hitchcock

Todd Macklin

Jason W Brown

Kristin Schleicher

Betty Lam

Mark E Adams

David S Weinstein

Jason Green

Benjamin Horning

Don Rogness

Kelsey Lamb

Robert Malmstrom

Zachary Owyang

Steve Hitchcock

Larry Burgess

Hukai Sun

Holdger Monenschein

Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R, R, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

Pharmaceutical compositions comprising WRN helicase inhibitors

The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.

Substituted pyrido[3,4-b]pyrazines as GPR6 modulators

Tetrahydropyridopyrazines as modulators of GPR6

The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

5-HT3 receptor antagonists

Disclosed is a compound of Formula 1, and a pharmaceutically acceptable salt thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with GPR6.

Tetrahydropyridopyrazine modulators of GPR6

Pyrazines as modulators of GPR6

The present invention provides compounds of Formula (I): that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesias, Huntington's disease, other dyskinesias, akinesias, and motor disorders involving dysfunction of the striatum, schizophrenia and drug addiction. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Quinoxaline derivatives as GPR6 modulators

This present invention provides compounds of formula II: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.

The present invention provides compounds of the formula: that are 5HT3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Growing community of inventors

San Diego, CA, United States of America

Shota Kikuchi